For the first time, a very large trial has shown that dual antiplatelet therapy (DAPT)\u00a0improves\u00a0cardiovascular outcomes when given to patients 1 to 3 years after a myocardial infarction. Because DAPT has been shown previously to\u00a0reduce the high risk of recurrent events for up to a year following an MI, it is considered to be standard therapy during\u00a0this time period. But whether or not\u00a0longer-term treatment after a year would be also beneficial has been controversial.<\/p>\n
AstraZeneca today\u00a0announced<\/a>\u00a0that the\u00a0Pegasus-TIMI 54<\/a>\u00a0study had successfully reached its primary endpoint. More than 21,000 patients\u00a0were randomized to receive either ticagrelor (Brilinta, 60 or 90 mg twice daily) or placebo in addition to aspirin. Therapy was initiated 1 to 3 years after MI in patients who also had one additional risk factor. The primary endpoint was the composite of cardiovascular death, MI, or stroke. The company said that no safety issues had been found and that the full results of the trial would be presented later this year.<\/p>\n Pegasus-TIMI 54 is the second in a series of trials sponsored by\u00a0AstraZeneca\u00a0exploring a broad range of indications for ticagrelor. PLATO, the first trial, earned FDA approval of the drug for an ACS indication, but the drug has labored under intense criticism of the trial.\u00a0In recent months, some of this criticism has\u00a0started to resolve<\/a>. Additional trials are now underway testing ticagrelor’s role in patients with peripheral arterial disease, with ischemic stroke or TIA, and with diabetes and coronary atherosclerosis.<\/p>\n <\/p>\n <\/p>\n <\/p>\n","protected":false},"excerpt":{"rendered":" For the first time, a very large trial has shown that dual antiplatelet therapy (DAPT)\u00a0improves\u00a0cardiovascular outcomes when given to patients 1 to 3 years after a myocardial infarction. Because DAPT has been shown previously to\u00a0reduce the high risk of recurrent events for up to a year following an MI, it is considered to be standard […]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[495,1],"tags":[364,464,245,240,658],"class_list":["post-46560","post","type-post","status-publish","format-standard","hentry","category-anticoagulation-2","category-general","tag-aspirin","tag-dapt","tag-mi","tag-ticagrelor","tag-timi"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/46560","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=46560"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/46560\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=46560"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=46560"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=46560"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}